Innovation in the healthcare sector in New York is exciting and extensive. Please join us to meet startups, CEOs, investors and industry experts at Invest NY: Health. The event will be held in March in Buffalo, NY and online.
The event will take place at the Center of Excellence Bioinformatics Life Sciences at the University at Buffalo, 701 Ellicott St., Buffalo, NY 14203 and online. If you’re planning to attend in-person, please read the COVID policy. Register today to:
Invest NY: Health Startup Showcase Meet 15 – 20 HealthIT, medical devices and life sciences startups innovating in New York
Networking & Tours
Invest NY: Health Program Featuring: – CEO Conversations – COVID Pivots – Buffalo to Boston: Empire Discovery Institute Update
Chief Executive Officer of The WNY Impact Investment Fund
Thomas is the Chief Executive Officer at the Western New York Impact Investment Fund. He has deep experience leading high growth entrepreneurial ventures, raising capital, and creating high-functioning management teams. Prior, he was President of Baton Pharma and Infonaut.
An energetic organizational professional experienced in the public and private sectors. I am the Executive Director of the MedTech Association, New York’s trade organization for the BioMed Industry. Our mission is to develop the relationships, tools and programs that enable New York State companies to bring tomorrow’s medical solutions to the healthcare marketplace.
Previously, I was Vice President for University Compliance and Ethics at SUNY Upstate Medical University where I oversaw the development and implementation of all university policies; coordinated and directed enforcement of regulations and policies related to ethics, compliance, institutional integrity and conflicts of interest; and developed and delivered education and training programs. I also served as the university’s Enterprise Risk Management Officer and its Internal Controls Officer. Prior to this position, I was Associate Counsel to the university .
I have also worked in various capacities in state government, most notably as Assistant Attorney General-in-Charge for the New York Attorney General from 1999 to 2007. There I managed the AG’s Central New York regional office and was responsible for enforcement of state regulatory requirements and the management of litigation, both affirmative and defensive. I began my legal career in private practice, where I specialized in civil litigation and bankruptcy.
In these various roles I have developed an expertise in compliance and ethics requirements and am a frequent lecturer on these topics. I also have extensive experience in communications, institutional messaging, crisis management, government relations, public speaking and legal analysis.
I have a J.D. degree from Georgetown University Law Center and a B.A. from Union College
Executive Director NYS Center of Excellence in Bioinformatics and Life Sciences at University at Buffalo
Norma Nowak is executive director of the New York State Center of Excellence in Bioinformatics & Life Sciences. She is an acclaimed researcher – a recognized leader in the human genomics field – and an entrepreneur. Her research contributed directly to the Human Genome Project, as well as to genomic-based approaches to understanding heritable disorders and cancer. Nowak is also the founder and chief scientific officer of Empire Genomics, LLC, a molecular diagnostics firm focused on enabling personalized medicine.
Nowak’s efforts were instrumental in obtaining more than $70 million in funding for research and infrastructure, and she has authored and co-authored 144 research articles. Among other achievements, she received the 2008 American Association of Cancer Research (AACR) Team Science Award and the 2008 Thomas B. Tomasi Award from Roswell Park Cancer Institute for her outstanding achievements in science. She is a Buffalo Museum of Science board member and was recently appointed to the Empire State Stem Cell Board for New York State and the founding board for 43North.
Nowak is also at the forefront of a new era of personalized medicine as a driving force in the governor’s investment in UB and the New York Genome Center (NYGC) to create the Buffalo Institute for Genomics and Data Analytics (BIG).
Chief Executive Officer at Empire Discovery Institute
Martin is an experienced drug developer and serial entrepreneur with over 30 years of experience in the research and development of small molecule drugs and biologics including Oxaliplatin (Eloxatin®) for colorectal cancer, Infliximab (Remicade®) for rheumatoid arthritis, Rasburicase (Elitek®) for the treatment of tumor lysis syndrome and Ustekinumab (Stelara®) for plaque psoriasis. He brings a wealth of pharmaceutical industry experience from his time at Sterling-Winthrop, Sanofi, Centocor, Johnson & Johnson, and several venture-capital backed biotechnology companies including TetraLogic Pharmaceuticals. He also has extensive experience working on regulatory submissions and approvals with the FDA (US) and EMA (Europe). Prior to joining the Empire Discovery Institute (EDI) as CEO, Martin was the founder, president and CEO of PKPD Biosciences, a pharmaceutical technology company which he later merged with his second company KinderPharm (a pediatric drug development company) before being successfully acquired by Synteract. Martin earned his PhD. from the University of London Drug Development Section, Institute of Cancer Research, Royal Marsden Hospital, London; his BSc. from the University of Leeds in Pharmacology and Microbiology; and is an Honorary Professor of Pharmacokinetic Modeling & Simulation at the School of Life Sciences, Institute of Pharmaceutical Innovation University of Bradford, England. In addition to his work at EDI, Martin serves as a Strategic Scientific Advisor to the Harrington Discovery Institute, a philanthropic drug discovery institute based in Cleveland, Ohio and BioMotiv the for-profit pharmaceutical accelerator associated with the Harrington Project.
Executive Director at CNY Biotech Accelerator, Upstate Medical University
CNY Biotech Accelerator, Upstate Medical University is a NYS Certified Business Incubator/ NYSTAR asset. CNYBAC provides licensable laboratory space at cost effective rates, shared equipment use and access to academic medical center clinical and basic science expert partnerships and core facilities. Clients can access Hot Spot and START-UP NY tax benefit programs and are provided MedTech annual membership. CNYBAC staff, mentors and ecosystem partners provide a wealth of resources and collaborative services to include student intern match assistance, networking opportunities and educational programming. Programs include the Empire State Development co-funded Medical Device Innovation Challenge, annual Manufacturing Workshop and Innovation Conference as well as the monthly-held CNYBAC Concept to Commercialization Virtual Series.
Paula Jaye Doyle, M.D. is a reconstructive pelvic surgeon at the University of Rochester and the Founder of EndoGlow. Dr. Doyle developed the fluorescent polymer (Tissue Reveal Technology™) during her fellowship after recognizing a clinical need. She currently sits on the Board of Biomedical Research Development at the University of Rochester and teaches post-graduate courses on Medical Innovation and Entrepreneurship. www.endoglow.com
Melissa Bime is the CEO of Infiuss Health, which is a SAAS platform for powering remote clinical research and clinical trials in Africa. Prior to starting this company, Melissa Had previously build software for blood donor recruitment and blood delivery. She has experience with building and operating clinical software and a really good understanding of building technology for the African Continent.
A hands-on, experienced and respected leader with deep experience in the African clinical Space, Health Information Technology with Operations, Strategy, International Development, Sales,and a solid track record of achievements impacting company Leaderdship, process/productivity improvements, cost containment and business development. Entrepreneur and strategic thinker.
Specialties: Patient Data & Engagement, Marketing, Compliance, Market Research.
MedTech is New York’s trade association for the bio/med industry. We are an innovative coalition of pharmaceutical, medical technology, and life sciences companies, research and academic institutions, suppliers, and service providers. We connect our member companies, entrepreneurs and academics to grow the region’s life sciences economy. Since our founding in 2004, we have boosted the success of our members through collaboration, education, and advocacy.
Repair Biotechnologies is a late preclinical-stage biotech company developing several first-in-class therapies based on their Cholesterol Degrading Platform (CDP), an innovative approach to treating the cause of medical conditions that arise due to localized accumulations of excess cholesterol.
VPG Medical is a digital health service company developing a unique set of monitoring solutions based on groundbreaking research using video-based sensors embedded in smart devices and personal computers.